Modern starches are not safer than old ones

Anesthesia and Analgesia

Volumn 109, Issue 4, 2009, Pages 1346-

  Hartog, Christiane ^a   Reinhart, Konrad ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HETASTARCH; DRUG DERIVATIVE; PLASMA SUBSTITUTE;

ABSENCE OF SIDE EFFECTS; BLOOD CLOTTING; CARDIAC PATIENT; DRUG ACCUMULATION; DRUG EFFECT; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART SURGERY; HUMAN; KIDNEY DYSFUNCTION; LETTER; LOW DRUG DOSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; KIDNEY FAILURE; NOTE; RISK ASSESSMENT; SAFETY; TISSUE DISTRIBUTION;

BLOOD COAGULATION; CONSUMER PRODUCT SAFETY; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HETASTARCH; HUMANS; KIDNEY FAILURE; PLASMA SUBSTITUTES; PRURITUS; RISK ASSESSMENT; TISSUE DISTRIBUTION;

EID: 70349569085     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181b366ad     Document Type: Letter

References (10)

1. Boldt J. Modern rapidly degradable hydroxyethyl starches: current concepts. Anesth Analg 2009;108:1574-1582
2. Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, Kukkonen SI, Niemi TT. Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Anesth Analg 2009;108:30-36
3. Hagne C, Schwarz A, Gaspert A, Giambarba C, Keusch G. HAES in septic shock - sword of Damocles? Schweiz Med Forum 2009;9:304-306 Available at: www.medicalforum.ch
4. FDA: Center for Biologics Evaluation and Research. Product approval information - new drug applications. NDA Review Memo (MID-CYCLE), 2007. Last updated April 10, 2008. Available at: http://www.fda.gov/ CbER/nda/voluven.htm. Accessed September 10, 2008
5. Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M. Hydrops lysosomalis generalisatus - an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006;77:83-85
6. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F. Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003;4:331-338 (Pubitemid 37407725)
7. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, Glotz D. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005;5:1120-1129 (Pubitemid 40571263)
8. Hartog C, Reinhart K. Pro/Con clinical debate: CONTRA: hydroxyethyl starch solutions are unsafe in critically ill patients. Intensive Care Med 2009 Jun 17 [Epub ahead of print] doi: 10.1007/500134-009-1521-5
9. Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hebert P, Bagshaw S, Monsour D, McIntyre LA. Renal outcomes following hydroxyethyl starch resuscitation: a meta-analysis of randomized trials. Intensive Care Med 2008;34:S91A
10. Tseng MY, Hutchinson PJ, Kirkpatrick PJ. Effects of fluid therapy following aneurysmal subarachnoid haemorrhage: a prospective clinical study. Br J Neurosurg 2008;22:257-268